Terns Pharma slips after scrapping obesity drug development

Terns Pharmaceuticals

22/10/2025 15:17

Updates

** Shares of drug developer Terns Pharmaceuticals TERN.O fall 6.4% to $7.60

** Company says it will discontinue the development of experimental obesity drug TERN-601 and not invest in other metabolic diseases after mid-stage trial failure

** Says the experimental drug led to maximum placebo-adjusted weight loss of 4.6%, with nearly 12% of the patients discontinuing the treatment due to side effects

** Three patients had reversible liver enzyme spikes after treatment, two deemed drug-related, company says

** TERN reaffirms focus on experimental blood cancer drug TERN-701 for chronic myeloid leukemia

** Including session's move, stock up ~33% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))